M T Connelly1, M Richardson, R Platt. 1. Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts, USA. maureen_connelly@hphc.org
Abstract
OBJECTIVE: To determine the prevalence and duration of postmenopausal hormone replacement therapy (HRT) use and identify correlates of adherence to therapy. DESIGN: Population-based cohort study. SETTING: Staff-model health maintenance organization. PARTICIPANTS: Female members, 40 years and older. MEASUREMENTS AND MAIN RESULTS: Prevalence and duration of use were measured between 1990 and 1995. Duration was assessed by Kaplan-Meier and proportional hazards methods. Hormone replacement therapy use increased from 10.3% in 1990 to 20.7% in 1995. Greatest use (24%) occurred among menopausal women age 50 to 54 years. Less than 5% of women 75 and older used HRT. Among 1,680 first-time recipients of HRT, two thirds of initial prescriptions were written by internists. Thirty-eight percent discontinued HRT within 1 year. For the subset whose indication for therapy was ascertained, prevention of chronic disease was associated with a 33% 1-year discontinuation rate. Factors associated with longer duration of therapy included white race (relative risk [RR], 1.63; 95% confidence interval [95% CI], 1.32 to 2.02), younger age (RR, 1.02 per year; 95% CI 1.01 to 1.03), and changing the preparation or dose of estrogen (RR, 5.62; 95% CI, 4.33 to 7.25). The formulation (esterified estrogens 0.625 mg versus conjugated estrogens 0.625 mg) was also associated with greater duration of use; all other estrogens were, as a group, associated with shorter duration of use. Those who received their initial HRT prescription from an internist were more likely to continue therapy than those who received it from a gynecologist. CONCLUSIONS: Despite increased use of HRT, only a minority of women in this population used HRT, and many of those discontinued therapy within 1 year.
OBJECTIVE: To determine the prevalence and duration of postmenopausal hormone replacement therapy (HRT) use and identify correlates of adherence to therapy. DESIGN: Population-based cohort study. SETTING: Staff-model health maintenance organization. PARTICIPANTS: Female members, 40 years and older. MEASUREMENTS AND MAIN RESULTS: Prevalence and duration of use were measured between 1990 and 1995. Duration was assessed by Kaplan-Meier and proportional hazards methods. Hormone replacement therapy use increased from 10.3% in 1990 to 20.7% in 1995. Greatest use (24%) occurred among menopausal women age 50 to 54 years. Less than 5% of women 75 and older used HRT. Among 1,680 first-time recipients of HRT, two thirds of initial prescriptions were written by internists. Thirty-eight percent discontinued HRT within 1 year. For the subset whose indication for therapy was ascertained, prevention of chronic disease was associated with a 33% 1-year discontinuation rate. Factors associated with longer duration of therapy included white race (relative risk [RR], 1.63; 95% confidence interval [95% CI], 1.32 to 2.02), younger age (RR, 1.02 per year; 95% CI 1.01 to 1.03), and changing the preparation or dose of estrogen (RR, 5.62; 95% CI, 4.33 to 7.25). The formulation (esterified estrogens 0.625 mg versus conjugated estrogens 0.625 mg) was also associated with greater duration of use; all other estrogens were, as a group, associated with shorter duration of use. Those who received their initial HRT prescription from an internist were more likely to continue therapy than those who received it from a gynecologist. CONCLUSIONS: Despite increased use of HRT, only a minority of women in this population used HRT, and many of those discontinued therapy within 1 year.
Authors: Sybil L Crawford; Carolyn J Crandall; Carol A Derby; Samar R El Khoudary; L Elaine Waetjen; Mary Fischer; Hadine Joffe Journal: Menopause Date: 2018-12-21 Impact factor: 2.953
Authors: Sengwee Toh; Sonia Hernández-Díaz; Roger Logan; Jacques E Rossouw; Miguel A Hernán Journal: Ann Intern Med Date: 2010-02-16 Impact factor: 25.391
Authors: Roseanne DeFronzo Dobkin; Matthew Menza; Karina L Bienfait; Lesley A Allen; Humberto Marin; Michael A Gara Journal: Menopause Int Date: 2009-03
Authors: Miguel A Hernán; Alvaro Alonso; Roger Logan; Francine Grodstein; Karin B Michels; Walter C Willett; Joann E Manson; James M Robins Journal: Epidemiology Date: 2008-11 Impact factor: 4.822
Authors: Alexandra Papaioannou; George Ioannidis; Jonathan D Adachi; Rolf J Sebaldt; Nicole Ferko; Mark Puglia; Jacques Brown; Alan Tenenhouse; Wojciech P Olszynski; Pauline Boulos; David A Hanley; Robert Josse; Timothy M Murray; Annie Petrie; Charlie H Goldsmith Journal: Osteoporos Int Date: 2003-09-11 Impact factor: 4.507